Semaglutide

Description

Semaglutide is a glucagon-like peptide-1 (GLP-1) agonist, which is a new generation of long-acting GLP-1 analogs. Semaglutide exerts the effects of regulating blood sugar levels and long-term weight management by mimicking natural GLP-1 and binding to the receptor.

Clinical Research Application

Type 2 diabetics

More than 90% of adults with diabetes are type 2 diabetics. With hundreds of millions of patients worldwide, type 2 diabetes has become one of the most serious public health challenges. Semaglutide promotes the synthesis and secretion of insulin by pancreatic β-cells and inhibits the secretion and release of glucagon by pancreatic α-cells in a glucose-dependent manner, thus effectively lowering blood glucose.

Obesity

As a chronic and recurrent metabolic disorder, obesity is often associated with adiposity, insulin resistance and cardiovascular disease. Semaglutide can activate appetite suppressing neuropeptides in the hypothalamus region, thereby delaying gastric emptying and increasing postprandial satiety, which is expected to open up a new horizon for obesity treatment.

Other potential applications

Other studies have shown that Semaglutide can be used in the treatment of cardiovascular diseases, non-alcoholic fatty liver disease and neurological diseases through the mechanism of antioxidants, inhibition of pro-inflammatory factors and reduction of adipogenesis.

List of Commercial Drugs with Semaglutide as Active Ingredient